Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.
about
Phosphate binders for preventing and treating bone disease in chronic kidney disease patientsPhosphate control in dialysisFerric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.Clinical and economic aspects of sevelamer therapy in end-stage renal disease patients.Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.New Conclusions Regarding Comparison of Sevelamer and Calcium-Based Phosphate Binders in Coronary-Artery Calcification for Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials.Cost Effectiveness of Sucroferric Oxyhydroxide Compared with Sevelamer Carbonate in the Treatment of Hyperphosphataemia in Patients Receiving Dialysis, from the Perspective of the National Health Service in Scotland.Reduced use of erythropoiesis-stimulating agents and intravenous iron with ferric citrate: a managed care cost-offset model.Sevelamer carbonate for the treatment of hyperphosphatemia in patients with kidney failure (CKD III - V).Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.Phosphate binders in patients with chronic kidney disease.Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials.Design and baseline characteristics of the LANDMARK studyComparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis.Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients
P2860
Q24234036-9D232322-2289-4CA0-9416-9AFEF86CE5DBQ27025339-A5897AD4-26C6-4C1E-ABEF-A052FE653364Q30854189-E4B9F126-A165-4259-AB09-0AB570966DE8Q33610457-25FEE6F0-FD6B-4E2D-AE39-B9EED1015AAEQ35030613-5D909D52-EF70-4AC5-9032-873B01A42908Q35730847-79BECCE5-EEB0-4804-86F7-DA72B0D0E965Q36322947-610870C3-A3C9-4C38-949F-A6E6145A3F3CQ36825820-BCE5A062-C542-4F65-BF85-0BC37527679EQ37803240-FCA5F40A-C2BA-4392-BB7F-DB27C09F38EFQ38210438-E4959076-5784-40C8-A204-3CB80B293059Q39155279-2FAF6772-2F73-4DB3-ABD3-064608644D77Q39488157-FC1A87D4-FE20-4F6C-AF97-96E406341943Q41389097-93E1BD07-CB8B-4339-A4DB-8F6D7F8769BEQ44853372-945D4EBB-A555-4B9A-BF73-EFBE230CF225Q57218915-9D533176-1807-4B4F-9DEB-544B9E548881
P2860
Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Economic evaluation of sevelam ...... care & Medicaid services data.
@ast
Economic evaluation of sevelam ...... care & Medicaid services data.
@en
Economic evaluation of sevelam ...... care & Medicaid services data.
@nl
type
label
Economic evaluation of sevelam ...... care & Medicaid services data.
@ast
Economic evaluation of sevelam ...... care & Medicaid services data.
@en
Economic evaluation of sevelam ...... care & Medicaid services data.
@nl
prefLabel
Economic evaluation of sevelam ...... care & Medicaid services data.
@ast
Economic evaluation of sevelam ...... care & Medicaid services data.
@en
Economic evaluation of sevelam ...... care & Medicaid services data.
@nl
P2093
P2860
P356
P1476
Economic evaluation of sevelam ...... care & Medicaid services data.
@en
P2093
Eric Weinhandl
Jiannong Liu
P2860
P304
P356
10.2215/CJN.04100609
P577
2009-10-15T00:00:00Z